prednisolone has been researched along with Minimal Disease, Residual in 20 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Availability of measurement of minimal residual disease (MRD) at an early time point with a reduced-cost method is of clinical relevance." | 2.74 | Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. ( Arico, M; Basso, G; Benetello, A; Biondi, A; Buldini, B; Conter, V; Dworzak, MN; Gaipa, G; Maglia, O; Masera, G; Ratei, R; Silvestri, D; Valsecchi, MG; Veltroni, M, 2009) |
| "In children with acute lymphoblastic leukemia (ALL), the level of minimal residual disease (MRD) at the end of induction strongly predicts outcome, presumably because it measures both drug sensitivity and the number of leukemic cells requiring elimination." | 2.68 | Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. ( Bradstock, K; Brisco, J; Enno, A; Hughes, E; McCaul, K; Morley, AA; Neoh, SH; Sykes, PJ; Szer, J, 1996) |
| "Even though acute lymphoblastic leukemia (ALL) responds well to chemotherapy, relapse remains the major problem." | 2.41 | Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy. ( Botsonis, A; Moschovi, M; Papadopoulou, AL; Tsangaris, GT; Tzortzatou-Stathopoulou, F, 2001) |
| "acute lymphoblastic leukemia-type chemotherapy that incorporated high-dose cytarabine was effective in achieving an minimal residual disease-negativity rate of 69% in evaluated patients, which was also predictive of better outcome." | 1.56 | Clinicoepidemiologic Profile and Outcome Predicted by Minimal Residual Disease in Children With Mixed-phenotype Acute Leukemia Treated on a Modified MCP-841 Protocol at a Tertiary Cancer Institute in India. ( Banavali, S; Gujral, S; Myint, HH; Narula, G; Patkar, N; Prasad, M; Subramanian, P; Tandon, S; Tembhare, P, 2020) |
| "Multivariate analysis revealed that minimal residual disease positive and time interval between induction IA and Protocol M of more than 70 days were independent adverse factors for EFS and OS." | 1.51 | Long-term outcomes of modified BFM-95 regimen in adults with newly diagnosed standard-risk acute lymphoblastic leukemia: a retrospective single-center study. ( Cai, X; Chen, X; Li, C; Liang, Y; Wang, H; Xia, Z, 2019) |
| "The ratio of minimal residual disease was 0." | 1.38 | [Detection and impact of minimal residual disease on outcome of chronic lymphocytic leukemia]. ( Bozsó, T; Iványi, JL; Plander, M; Skrapits, J; Szendrei, T, 2012) |
| "t(12;21)(p1 3;q22), the most frequent chromosomal translocation found in childhood acute lymphoblastic leukemia (ALL), occurs in approximately 25% of B-lineage ALL cases and has been claimed to carry a good prognosis." | 1.32 | Post-induction residual disease in translocation t(12;21)-positive childhood ALL. ( Clausen, N; Jonmundsson, GK; Madsen, HO; Nyvold, C; Ryder, LP; Schmiegelow, K; Seyfarth, J; Wesenberg, F, 2003) |
| "Most prognostic factors in childhood acute lymphoblastic leukemia (ALL) are informative for groups of patients, whereas new approaches are needed to predict the efficacy of chemotherapy for the individual patient." | 1.31 | Post-induction residual leukemia in childhood acute lymphoblastic leukemia quantified by PCR correlates with in vitro prednisolone resistance. ( Kaspers, GJ; Knabe, N; Madsen, HO; Nyvold, C; Pieters, R; Rottier, MM; Ryder, LP; Schmiegelow, K; Seyfarth, J; Svejgaard, A, 2001) |
| "However, minimal residual disease (MRD) detected with DEK/CAN chimeric m-RNA by reverse transcription polymerase chain reaction (RT-PCR) was continuously observed, although decreased quantitatively, following several courses of consolidation and intensification chemotherapies." | 1.30 | [The detection of minimal residual disease by DEK/CAN chimeric m-RNA in a case of AML M2 with translocation t(6;9) (p23;q34) after chemotherapy and peripheral blood stem cell transplantation]. ( Ando, T; Ariyoshi, K; Hikiji, K; Kobayashi, M; Shinohara, K; Toyosawa, M, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 10 (50.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Myint, HH | 1 |
| Tandon, S | 1 |
| Narula, G | 1 |
| Prasad, M | 1 |
| Subramanian, P | 1 |
| Patkar, N | 1 |
| Tembhare, P | 1 |
| Gujral, S | 1 |
| Banavali, S | 1 |
| Li, C | 1 |
| Cai, X | 1 |
| Chen, X | 1 |
| Liang, Y | 1 |
| Xia, Z | 1 |
| Wang, H | 1 |
| Mei, YY | 1 |
| Gao, C | 1 |
| Cui, L | 1 |
| Zhao, XX | 1 |
| Zhao, W | 1 |
| Li, WJ | 1 |
| Wang, KL | 1 |
| Jiang, J | 1 |
| Zhang, RD | 1 |
| Xie, J | 1 |
| Shi, HW | 1 |
| Wang, B | 1 |
| Zhang, YH | 1 |
| Ma, XL | 1 |
| Zhou, X | 1 |
| Wu, MY | 1 |
| Li, ZG | 1 |
| Koh, K | 1 |
| Tomizawa, D | 1 |
| Moriya Saito, A | 1 |
| Watanabe, T | 1 |
| Miyamura, T | 1 |
| Hirayama, M | 1 |
| Takahashi, Y | 1 |
| Ogawa, A | 1 |
| Kato, K | 1 |
| Sugita, K | 1 |
| Sato, T | 1 |
| Deguchi, T | 1 |
| Hayashi, Y | 1 |
| Takita, J | 1 |
| Takeshita, Y | 1 |
| Tsurusawa, M | 1 |
| Horibe, K | 1 |
| Mizutani, S | 1 |
| Ishii, E | 1 |
| Kim, DY | 1 |
| Joo, YD | 1 |
| Lim, SN | 1 |
| Kim, SD | 1 |
| Lee, JH | 3 |
| Kim, DH | 1 |
| Kim, K | 1 |
| Jung, CW | 1 |
| Kim, I | 1 |
| Yoon, SS | 1 |
| Park, S | 1 |
| Ahn, JS | 1 |
| Yang, DH | 1 |
| Lee, JJ | 1 |
| Lee, HS | 1 |
| Kim, YS | 1 |
| Mun, YC | 1 |
| Kim, H | 1 |
| Park, JH | 1 |
| Moon, JH | 1 |
| Sohn, SK | 1 |
| Lee, SM | 1 |
| Lee, WS | 1 |
| Kim, KH | 1 |
| Won, JH | 1 |
| Hyun, MS | 1 |
| Park, J | 1 |
| Shin, HJ | 1 |
| Chung, JS | 1 |
| Lee, H | 1 |
| Eom, HS | 1 |
| Lee, GW | 1 |
| Cho, YU | 1 |
| Jang, S | 1 |
| Park, CJ | 1 |
| Chi, HS | 1 |
| Lee, KH | 1 |
| Campana, D | 1 |
| Pui, CH | 1 |
| Lönnerholm, G | 2 |
| Thörn, I | 2 |
| Sundström, C | 2 |
| Frost, BM | 2 |
| Abrahamsson, J | 1 |
| Behrendtz, M | 1 |
| Heldrup, J | 1 |
| Jacobsson, S | 1 |
| Li, A | 1 |
| Olofsson, T | 1 |
| Porwit, A | 2 |
| Söderhäll, S | 2 |
| Larsson, R | 2 |
| Forestier, E | 2 |
| Basso, G | 1 |
| Veltroni, M | 1 |
| Valsecchi, MG | 1 |
| Dworzak, MN | 1 |
| Ratei, R | 1 |
| Silvestri, D | 1 |
| Benetello, A | 1 |
| Buldini, B | 1 |
| Maglia, O | 1 |
| Masera, G | 1 |
| Conter, V | 1 |
| Arico, M | 1 |
| Biondi, A | 1 |
| Gaipa, G | 1 |
| Flaegstad, T | 1 |
| Heyman, M | 1 |
| Jonsson, OG | 1 |
| Harila-Saari, A | 1 |
| Madsen, HO | 3 |
| Schmiegelow, K | 3 |
| Wesenberg, F | 2 |
| Vettenranta, K | 1 |
| Lauten, M | 1 |
| Möricke, A | 1 |
| Beier, R | 1 |
| Zimmermann, M | 1 |
| Stanulla, M | 1 |
| Meissner, B | 1 |
| Odenwald, E | 1 |
| Attarbaschi, A | 1 |
| Niemeyer, C | 1 |
| Niggli, F | 1 |
| Riehm, H | 1 |
| Schrappe, M | 1 |
| Krejci, M | 1 |
| Doubek, M | 1 |
| Brychtova, Y | 1 |
| Stehlikova, O | 1 |
| Chovancova, J | 1 |
| Tichy, B | 1 |
| Francova, HS | 1 |
| Navratil, M | 1 |
| Tomiska, M | 1 |
| Horky, O | 1 |
| Pospisilova, S | 1 |
| Mayer, J | 1 |
| Plander, M | 1 |
| Skrapits, J | 1 |
| Bozsó, T | 1 |
| Szendrei, T | 1 |
| Iványi, JL | 1 |
| Styczynski, J | 1 |
| Piatkowska, M | 1 |
| Jaworska-Posadzy, A | 1 |
| Czyzewski, K | 1 |
| Kubicka, M | 1 |
| Kolodziej, B | 1 |
| Kurylo-Rafinska, B | 1 |
| Debski, R | 1 |
| Pogorzala, M | 1 |
| Wysocki, M | 1 |
| Seyfarth, J | 2 |
| Nyvold, C | 2 |
| Ryder, LP | 2 |
| Clausen, N | 1 |
| Jonmundsson, GK | 1 |
| Avilés, A | 1 |
| Neri, N | 1 |
| Delgado, S | 1 |
| Pérez, F | 1 |
| Nambo, MJ | 1 |
| Cleto, S | 1 |
| Talavera, A | 1 |
| Huerta-Guzmán, J | 1 |
| Hirt, C | 1 |
| Schüler, F | 1 |
| Kiefer, T | 1 |
| Schwenke, C | 1 |
| Haas, A | 1 |
| Niederwieser, D | 1 |
| Neser, S | 1 |
| Assmann, M | 1 |
| Srock, S | 1 |
| Rohrberg, R | 1 |
| Dachselt, K | 1 |
| Leithäuser, M | 1 |
| Rabkin, CS | 1 |
| Herold, M | 1 |
| Dölken, G | 1 |
| Brisco, J | 1 |
| Hughes, E | 1 |
| Neoh, SH | 1 |
| Sykes, PJ | 1 |
| Bradstock, K | 1 |
| Enno, A | 1 |
| Szer, J | 1 |
| McCaul, K | 1 |
| Morley, AA | 1 |
| Toyosawa, M | 1 |
| Shinohara, K | 1 |
| Ariyoshi, K | 1 |
| Ando, T | 1 |
| Kobayashi, M | 1 |
| Hikiji, K | 1 |
| Pieters, R | 1 |
| Rottier, MM | 1 |
| Knabe, N | 1 |
| Svejgaard, A | 1 |
| Kaspers, GJ | 1 |
| Tzortzatou-Stathopoulou, F | 1 |
| Papadopoulou, AL | 1 |
| Moschovi, M | 1 |
| Botsonis, A | 1 |
| Tsangaris, GT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Tasigna® (Nilotinib) Plus Multi-Agent Chemotherapy for Newly-Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia[NCT00844298] | Phase 2 | 91 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph-positive Acute Lymphoblastic Leukemia[NCT04554459] | Phase 2 | 32 participants (Anticipated) | Interventional | 2021-02-16 | Active, not recruiting | ||
| Treatment Protocol for Newky Diagnosed Adult Ph-Chromosome Positive (BCR::ABL1) Acute Lymphoblastic Leukemia (LALPh2022)[NCT06175702] | 150 participants (Anticipated) | Observational | 2023-12-25 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
approximate time: at the recovery of cytopenia (NCT00844298)
Timeframe: 1 month
| Intervention | percentage of analyzable subjects (Number) |
|---|---|
| Nilotinib+mVPD | 91 |
2 reviews available for prednisolone and Minimal Disease, Residual
| Article | Year |
|---|---|
Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child, Preschool; Cyclophosphamide; Da | 2017 |
Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Bone Marrow T | 2001 |
7 trials available for prednisolone and Minimal Disease, Residual
| Article | Year |
|---|---|
Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Drug Administ | 2015 |
Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Drug Administ | 2015 |
Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Drug Administ | 2015 |
Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Drug Administ | 2015 |
Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Drug Administ | 2015 |
Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Drug Administ | 2015 |
Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Drug Administ | 2015 |
Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Drug Administ | 2015 |
Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Drug Administ | 2015 |
Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dexamethasone; | 2009 |
Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers; Bone Marrow; Child; Child, | 2012 |
Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antin | 2013 |
Residual disease after chemotherapy in aggressive malignant lymphoma: the role of radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 2005 |
Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2008 |
Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; | 1996 |
11 other studies available for prednisolone and Minimal Disease, Residual
| Article | Year |
|---|---|
Clinicoepidemiologic Profile and Outcome Predicted by Minimal Residual Disease in Children With Mixed-phenotype Acute Leukemia Treated on a Modified MCP-841 Protocol at a Tertiary Cancer Institute in India.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; | 2020 |
Long-term outcomes of modified BFM-95 regimen in adults with newly diagnosed standard-risk acute lymphoblastic leukemia: a retrospective single-center study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Asparaginase; Cohort Studies; C | 2019 |
[Evaluation of the efficacy of two successive protocols on pediatric acute lymphoblastic leukemia with E2A-PBX1 fusion gene].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Daunorubicin; D | 2013 |
Early use of allogeneic hematopoietic stem cell transplantation for infants with MLL gene-rearrangement-positive acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Child, Preschool; Disease-Free Survival; Female; Gene Rearrangement; Hematopo | 2015 |
In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Doxorubicin; Hu | 2009 |
In vitro cellular drug resistance adds prognostic information to other known risk-factors in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells | 2011 |
[Detection and impact of minimal residual disease on outcome of chronic lymphocytic leukemia].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival | 2012 |
Comparison of prognostic value of in vitro drug resistance and bone marrow residual disease on day 15 of therapy in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents; Asparaginase; Bone Marrow; Child; Child, Preschool; Daunorubicin; | 2012 |
Post-induction residual disease in translocation t(12;21)-positive childhood ALL.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosomes, Hu | 2003 |
[The detection of minimal residual disease by DEK/CAN chimeric m-RNA in a case of AML M2 with translocation t(6;9) (p23;q34) after chemotherapy and peripheral blood stem cell transplantation].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 6; Chromosomes, | 1997 |
Post-induction residual leukemia in childhood acute lymphoblastic leukemia quantified by PCR correlates with in vitro prednisolone resistance.
Topics: Adolescent; Child; Child, Preschool; Drug Resistance, Neoplasm; Humans; Infant; Neoplasm, Residual; | 2001 |